Improving Outcomes in BRAF-Mutant mCRC Through Screening and Targeted Therapy

October 11, 2021 - October 11, 2022

Overview

In this webcast, expert faculty discuss the role of BRAF and other biomarkers in guiding treatment decisions, the importance of biomarker screening, and how to implement screening results to make appropriate treatment decisions as well as discussion of the side effect profiles of BRAF-specific therapy and effectively managing adverse events.

This webcast increases educational opportunities to all members of the cancer care team and increase their understanding of the role of BRAF mutations and the role of biomarker testing through the review of the safety and efficacy of approved targeted BRAF-mutant mCRC treatments and development of strategies to anticipate and mitigate side effects from treatments for BRAF-mutant mCRC.

Target Audience
Physicians, oncology nurse practitioners (NPs), physician assistants (PAs), nurse specialists, pharmacists and other health care providers involved in the management of oncology patients.

Learning Objectives

  1. Describe the role of BRAF mutations in mCRC oncogenesis and prognosis

  2. Discuss the role of biomarker testing in treating mCRC
  3. Review the safety and efficacy of approved targeted BRAF-mutant mCRC treatments
  4. Implement strategies to anticipate and mitigate side effects from treatments for BRAF-mutant mCRC.

Activity Launch Date - 10/11/21
Expiration Date - 10/11/22

Disclosure of Commercial Support
This activity is supported by an independent educational grant from Pfizer.

Disclosure of Unlabeled Use
Horizon CME requires that faculty participating in any CME activity disclose to the audience when discussing any unlabeled or investigational use of any commercial product or device not yet approved for use in the United States.

Disclaimer
This activity is designed for educational purposes. Participants have a responsibility to utilize this information to enhance their professional development to improve patient outcomes. Conclusions drawn by the participants should be derived from careful consideration of all available scientific information. The participant should use his/her clinical judgment, knowledge, experience, and diagnostic decision-making before applying any information, whether provided here or by others, for any professional use.

Statement of Independence
Horizon CME educational activities are developed and conducted in accordance with the ACCME's Essential Areas and Policies. It is the mission of Horizon CME to develop and present educational activities that are timely, fair balanced, scientifically rigorous, and that serve to improve patient outcomes. To that end, we welcome comments about how to better serve your needs.

Copyright Information
Copyright © 2021 - All rights reserved. This CME-certified program is held as copyrighted by Horizon CME. Through this notice, Horizon CME grants permission of its use for educational purposes only. These materials may not be used, in whole or in part, for any commercial purposes without prior permission in writing from the copyright owners.

Agenda

Time Description

Pre-test

Webcast

Post-test

Evaluation

CME Information

ANCC

This activity has been planned and implemented in accordance with the accreditation requirements and policies of the American Nurses Credentialing Center’s Commission on Accreditation through the joint providership of the Nurse Practitioner Healthcare Foundation and Horizon CME.

The Nurse Practitioner Healthcare Foundation is accredited as a provider of nursing continuing professional development by the American Nurses Credentialing Center’s Commission on Accreditation. NPHF is awarding the contact hours and is responsible for adherence to the ANCC criteria. Upon completion, NPs and RNs will be awarded up to 1.0 contact hours and up to 0.75 pharmacology hours.



ACPE

The Washington State Pharmacy Association is accredited by the Accreditation Council for Pharmacy Education as a Provider of continuing pharmacy education.

This conference is approved for up to 1.0 credit hours by the Washington State Pharmacy Association.

ACPE # 0130-9999-21-344-H01-P | Activity Type: Application

Additional ACPE Requirements
In order to process CE credits, participants must have provided the correct NABP e-Profile IDnumber and their birth month and day (MMDD format) in the evaluation survey. The NABP eProfile ID number is a six to eight-digit number, and it is NOT your license number, NPI number,or store NABP#. If you need to verify your number or have not yet registered for one, pleasevisit www.MyCPEMonitor.net.

The Washington State Pharmacy Association only has 60 days from the date you completed the enduring material to upload the CPE information to the CPE Monitor. It will be your responsibility to check the CPE Monitor before the 60 days to make sure the CE is uploaded in your profile. If there are any problems, you will need to contact WSPA 425-228-7171.

The CPE information will be uploaded to the CPE Monitor up to 50 days following the date you completed the enduring material. Please check your CPE Monitor at this time to ensure the CE is uploaded in your profile.


AMA PRA Category 1 Credit(s)

Accreditation Statement
Horizon CME is accredited by the Accreditation Council for Continuing Medical Education to provide continuing medical education for physicians.

Credit Designation
Horizon CME designates this live activity for a maximum of 1.0 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.




How To Claim Credit

  • There are no fees to participate in the activity.
  • Participants must review all activity information, including the learning objectives, disclosure statements, and content.
  • To receive CME credit, participants must complete the activity and the post-activity evaluation.
  • Certificates can be printed immediately

Faculty

Kathleen Boyle, PA-C
Physician Assistant
Dana-Farber Cancer Institute
Boston MA

Kathleen Boyle is a physician assistant (PA) at Dana-Farber Cancer Institute’s (DFCI) Gastrointestinal Cancer Center based in Boston, Massachusetts. Ms. Boyle holds a Bachelor of Science in biology and a Bachelor of Science in environmental studies from Fordham University. She holds a Master of Science in medical studies from Yale University School of Medicine. She is currently enrolled at Massachusetts College of Pharmacy and Health Sciences University as a candidate for a Doctor of Science in Physician Assistant Studies.

Prior to joining DFCI, she was an Emergency Department PA at Yale-New Haven Hospital’s St. Raphael’s Campus Emergency Department and a Thoracic Oncology Service PA at New York-Presbyterian Hospital Columbia Medical Center. At DFCI she has held roles in the inpatient medical oncology unit, the thoracic medical and surgical oncology divisions, and the gastrointestinal medical oncology division. Ms. Boyle has spoken professionally at local and national conferences including giving the “Updates in Colon Cancer” lecture at the Association of Physician Assistants in Oncology 22nd Annual Symposium, giving the “Improving Outcomes for Patients with Metastatic Colorectal Cancer: Challenges and Strategies” lecture at the Journal for Advanced Practitioners of Oncology Live Annual Meeting 2019, and giving the “Molecular Profiling of Thoracic and Gastrointestinal Malignancies and Options in Targeted Therapy” lecture at DFCI Medical Grand Rounds. Ms. Boyle has taught the MGH Institute for Health Professions PA program module on lung cancer and lung nodules annually since 2018. She was awarded the DFCI Distinguished Physician Assistant award in 2020 and is a nominated member of the Brigham and Women’s Hospital Peer Support Program since 2020.


Name of Faculty/ Reported Financial Relationship

Kathleen Boyle has not had any relevant financial relationships within the past 12 months with any entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients.

Planner Disclosures

Those involved in the planning of this activity disclosed no relevant financial relationships with any entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients during the past 12 months.

Other Contributor/Planner Disclosures

Non-faculty contributors and others involved in the planning, development, and editing/review of the content disclose no relevant financial relationships with any entity producing, marketing, re-selling, or distributing health care goods or services consumed by, or used on, patients during the past 12 months..

Learner Assurance Statement
Horizon CME requires instructors, planners, managers and other individuals who are in a position to influence the content of this activity to disclose any real or apparent conflict of interest (COI) which may arise as a result of prospective faculty members' relevant relationships with drug or device manufacturer(s). Horizon CME is committed to resolving all conflicts of interest and retaining only those speakers with financial interest conflicts that can be reconciled with the goals and educational integrity of the CME activity.

Any questions? Please check out our FAQs section or feel free to contact us.